Jazz Pharma Plc (JAZZ) 142.40 $JAZZ Hercules Provides

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 10:21 AM

Jazz Pharma Plc (JAZZ) 142.40 $JAZZ

Hercules Provides Portfolio Update for Q2 2016 and Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy
BusinessWire - Tue Jul 05, 10:34AM CDT
--Over $6.0 Billion in Total Debt Commitments Milestone achieved (since inception December 2003)
CPXX: 30.25 (+0.01), HTGC: 12.50 (unch), GCI: 13.85 (+0.04), PFE: 36.08 (-0.04), JAZZ: 142.40 (+2.52), ANAC: 99.06 (-0.14), RLOC: 4.56 (unch), EACQ: 9.93 (+0.03)

Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition
PR Newswire Europe - Sun Jun 26, 11:10PM CDT
Jazz Pharmaceuticals plc announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"

, with respect to its proposed acquisition of Celator Pharmaceuticals, Inc. expired effective June 24, 2016, at 11:59 p.m. (Eastern Daylight Time).
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 142.40 (+2.52)

Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 142.40 (+2.52)

Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 56.50 (-0.01), JAZZ: 142.40 (+2.52), PFE: 36.08 (-0.04), BMY: 75.26 (-0.02)

Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"

(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz"

.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.28 (+0.14), JAZZ: 142.40 (+2.52), GRFS: 17.06 (+0.14), PBYI: 35.73 (+0.85)

Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company"

in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz"

. On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 142.40 (+2.52)

Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 142.40 (+2.52)

CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator"

(NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.25 (+0.01), GXP: 30.88 (-0.32), WR: 56.22 (-0.20), MDT: 88.37 (+0.01), JAZZ: 142.40 (+2.52)

Shareholder Alert: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Celator Pharmaceuticals, Inc. - CPXX
PR Newswire - Tue May 31, 3:29PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Celator Pharmaceuticals Inc. ("Celator" or the "Company"

(NASDAQ: CPXX) (ISIN: US15089R1023) (CUSIP: 15089R102) concerning the proposed acquisition of Celator by Jazz Pharmaceuticals plc.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX
ACCESSWIRE - Tue May 31, 11:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
PR Newswire Europe - Tue May 31, 2:30AM CDT
Transaction would add VYXEOS(TM), an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc
BusinessWire - Fri May 27, 1:47PM CDT
Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company"

(NASDAQ:JAZZ) concerning possible violations of federal securities laws.
JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ
PR Newswire - Fri May 27, 10:41AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
JAZZ: 142.40 (+2.52)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...